Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
probiotic lactobacilli
- Development stage
- Unknown
- Lead developer
- Melbourne Health
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Enteral
01
Overview
Probiotic lactobacilli (Melbourne Health) refers to a probiotic intervention consisting of specific Lactobacillus strains, including *Lactobacillus fermentum* VRI-003 and *Lactobacillus acidophilus*, investigated by Melbourne Health (Royal Melbourne Hospital) for the prevention of nosocomial pneumonia. Administered through enteral feeding to critically ill adult patients, these live biotherapeutic products are intended to modulate the gastrointestinal and respiratory microbiota. The mechanism of action involves stabilizing the gut flora to prevent the overgrowth and translocation of pathogenic bacteria, such as those causing ventilator-associated pneumonia, and enhancing the host's mucosal and systemic immune responses. By maintaining microbial balance and competitive exclusion of pathogens, the treatment aims to reduce the incidence of hospital-acquired infections in intensive care settings.
- Other names
- Lactobacillus fermentumLactobacillus acidophilusProbiotic Lactobacilluslactobacillus-Melbourne Health-pneumonia (nosocomial)
02
Targets
GP2 (Ebolavirus glycoprotein 2)
Beyond the preview
Go deeper on probiotic lactobacilli.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on probiotic lactobacilli.